QualityStocks.net News – SIGA Technologies Inc. (SIGA) Takes Steps toward FDA Approval for its Lead Smallpox Antiviral

At www.QualityStocks.Net you can sign up for Quality Stock's Daily Newsletter to find out what Small-Cap and Micro-Cap online Investment Newsletters are interested in, plus hear about the latest news from our clients as well as other publicly traded companies.

We would like to highlight SIGA Technologies Inc. (NASDAQ: SIGA). The company is a biotechnology company that discovers, develops, and commercializes anti-infectives, antibiotics and vaccines for serious infectious diseases. The focus of SIGA’s developmental and commercialization activities is on products for use in defense against biological warfare agents, such as smallpox and arenaviruses (hemorrhagic fevers).

In the Company’s news today,

SIGA Technologies Inc. (NASDAQ: SIGA) announced it has launched an initiative to produce DNA registration batches of its leading smallpox antiviral, ST-246. The company specializes in the development of pharmaceutical agents effective against biowarfare pathogens. For the past few months, the company has consulted with the FDA to choose its final chemical formulation for large-scale production, and has chosen the market image and packaging needed to commercialize the material.

“Now that we have submitted to FDA our package supporting emergency use authorization for ST-246 and have successfully completed a multiple ascending dose human clinical safety trial, we are moving to complete the other elements necessary to get full marketing approval,” Dr. Eric Rose, CEO of SIGA stated in the press release. “Scale up of the final formulation is complete, and manufacturing of the registration batches is underway. We expect to complete all registration batches of ST-246 in the second half of 2008.”

“Every step we take toward the commercialization of ST-246 is an important, value-driving milestone for SIGA and its shareholders. Given the success that this drug has demonstrated thus far in our efficacy studies, we believe that ST-246 can be the preferred antiviral option for defending against possible bio-terror and bio-warfare attacks using the smallpox virus,” he continued.

The company has secured a contract with Albemarle Corporation (NYSE: ALB), in which Albemarle will provide its scale-up and manufacturing services to produce three registration batches in anticipation of the upcoming pivotal safety clinical trial. To win FDA marketing approval, SIGA is required to manufacture “registration batches” - commercial amounts of ST-246 produced in accordance with the FDA’s current standards for good manufacturing practices.

About QualityStocks

QualityStocks.net, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks.net is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks.net website: http://Disclaimer.QualityStocks.net